Theracap ^131 aktywność od 37 MBq do 2035 MBq (co 37MBq) aktywność od 2,22 Gbq do 5,55 GBq (co 185 MBq) Kapsułki Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

theracap ^131 aktywność od 37 mbq do 2035 mbq (co 37mbq) aktywność od 2,22 gbq do 5,55 gbq (co 185 mbq) kapsułki

ge healthcare buchler gmbh & co. kg - natrii iodidum 131 j - kapsułki - aktywność od 37 mbq do 2035 mbq (co 37mbq) aktywność od 2,22 gbq do 5,55 gbq (co 185 mbq)

Plerixafor Accord Unia Europejska - polski - EMA (European Medicines Agency)

plerixafor accord

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Иммуностимуляторы, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.